Leishmaniasis is a protozoal infection transmitted by a sandfly vector. In Germany, leishmaniasis of the mucous membranes is a rare condition and usually due to extension of local skin disease into the mucosal tissue via direct extension, bloodstream or lymphatics. We report a case of endonasal leishmaniasis in a female German resident who presented in a university hospital with nasal obstruction. Histology of the left nasal septum biopsy was suggestive of leishmaniasis. The molecular detection of DNA was positive for leishmania infantum. The patient was successfully treated as a case of mucocutaneous leishmaniasis receiving liposomal amphotericin follow up visits showed significant improvement with no recurrence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572673 | PMC |
| http://dx.doi.org/10.11604/pamj.2020.36.292.24543 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
"High specificity of PCR in diagnosing mucocutaneous leshminiasis: a systematic review and meta analysis".
BMC Infect Dis
December 2024
Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan.
Background: Mucocutaneous leishmaniasis (MCL) is a severe form of leishmaniasis causing chronic and destructive lesions. Accurate diagnosis is crucial for effective treatment. Traditional methods, such as the Montenegro skin test is delayed hypersensitivity test.
View Article and Find Full Text PDFInstrument-Free Point-of-Care Diagnostic for Leishmania Parasites.
Diagnostics (Basel)
December 2024
Biological Mimetics, Inc., 124 Byte Drive, Frederick, MD 21702, USA.
Background/objective: Leishmaniasis is the second deadliest parasitic disease in the world, after malaria, with an estimated 1.6 million new cases each year. While cutaneous leishmaniasis can result in permanent scars from lesions after treatment, the mucocutaneous and visceral diseases can result in life-altering and life-threatening complications.
View Article and Find Full Text PDFHistopathological Patterns of Cutaneous and Mucocutaneous Leishmaniasis Due to .
Dermatol Res Pract
November 2024
Department of Communicable and Non Communicable Disease, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Cutaneous leishmaniasis (CL) is an endemic disease in Ethiopia, mainly caused by . Limited reports are available related to histopathological features of the skin lesion caused by . This study aimed to analyze the histopathological features of CL due to .
View Article and Find Full Text PDFAnti-leishmanial therapies: overcoming current challenges with emerging therapies.
Expert Rev Anti Infect Ther
December 2024
Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Introduction: Leishmaniasis, including visceral, cutaneous, and mucocutaneous forms, present a major health challenge in tropical regions. Current antileishmanial medications has significant limitations, creating a critical need for novel therapies that are safe and cost-effective with a shorter duration of treatment.
Areas Covered: This review explores the critical aspects of existing antileishmanial therapy and targets for future therapeutic developments.
An update on recombinant vaccines against leishmaniasis.
Indian J Med Res
December 2024
Department of Research, Sir Ganga Ram Hospital, New Delhi, India.
Leishmaniasis is a parasitic disease caused by various species of the Leishmania parasite, manifesting in visceral (VL), cutaneous (CL), and mucocutaneous (MCL) forms. To combat this debilitating disease, various vaccines candidates including proteins, DNA, vectors, adjuvants, and recombinant whole parasites have been developed and tested experimentally and preclinically against several Leishmania species. Some vaccines have already entered human clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!